Welcome to our dedicated page for Hca Healthcare news (Ticker: HCA), a resource for investors and traders seeking the latest updates and insights on Hca Healthcare stock.
HCA Healthcare operates a healthcare services network built around acute-care hospitals and ambulatory sites of care in the United States and the United Kingdom. Company news commonly addresses hospital operating trends, same-facility admissions, emergency room visits, inpatient and outpatient surgeries, revenue per equivalent admission and quarterly financial results.
Updates also cover capital allocation and financing activity, including dividends, share repurchase authorizations, commercial paper, senior notes issued by HCA Inc., and debt redemptions. Other recurring developments include hospital quality recognition, investor conference presentations, enterprise marketing and corporate affairs leadership, and the role of surgery centers, freestanding ERs, urgent care centers and physician clinics within HCA's ambulatory care platform.
HCA Healthcare (NYSE:HCA) plans to present at two healthcare conferences in September 2026: the Wells Fargo Healthcare Conference on September 9, 2026 at 10:15 a.m. ET and the Jefferies Healthcare Conference on September 15, 2026 at 1:50 p.m. CT.
According to HCA Healthcare, live audio webcasts (where available) and presentation materials will be accessible via the Investor Relations section of its website. The company notes that dates and times may change and advises checking conference schedules or its Investor Relations page for updates.
HCA Healthcare (NYSE:HCA) appointed Michael Schlosser, M.D., MBA, as executive vice president and chief clinical officer effective September 1, 2026, succeeding Dr. Michael Cuffe, who steps down August 31 and will serve as an executive consultant through February 2027. Dr. Schlosser, currently senior vice president and chief transformation officer, will report to CEO Sam Hazen and lead the Clinical Services Group, covering Quality, hospital Chief Medical Officers, Nursing, Graduate Medical Education, Hospital Based Services and other enterprise clinical functions.
He will also continue to oversee digital transformation, clinical informatics and enterprise strategies for electronic health records, digital technologies and data platforms. HCA Healthcare named Charles Gressle, now president of the East Florida Division, as president of a new Ambulatory Operations Group, also effective September 1. Reporting to COO Jon Foster, Gressle will lead the Physician Services Group, Surgery Ventures Group and related service lines, overseeing more than 2,700 facilities and clinics to improve integration across the company’s ambulatory network. Searches for successors to both leaders’ current roles are underway.
HCA Healthcare (NYSE:HCA) reported second quarter 2026 revenues of $20.23 billion, up 8.7% year over year, and net income attributable to HCA of $1.699 billion, or $7.62 diluted EPS (up 11.6%). Adjusted EBITDA rose 4.6% to $4.027 billion. Results include $1.372 billion of incremental revenues and $829 million of other operating expenses from the Florida directed payment program, with about $980 million of revenue and $557 million of expenses related to periods prior to 2026.
HCA cited a payer mix shift from higher uninsured volumes, estimating a ~$400 million unfavorable impact on income before taxes in the quarter, partially offset by roughly $400 million of incremental net benefit from Medicaid Supplemental Payment Programs. The company cut its 2026 guidance, narrowing revenue to $77.0–$79.5 billion and reducing projected net income, Adjusted EBITDA and EPS, while continuing a $0.78 quarterly dividend and repurchasing 4.752 million shares for $2.064 billion.
HCA Healthcare (NYSE: HCA) announced details for its 2nd quarter 2026 earnings conference call. The live webcast will take place on Friday, July 24, 2026, at 9:00 AM Central (10:00 AM Eastern) and will be accessible as live audio over the Internet.
Investors can access the event via HCA Healthcare’s investor relations website at https://investor.hcahealthcare.com/events-and-presentations/default.aspx. According to HCA Healthcare, a replay of the call will be archived on the same site for later listening. Investor inquiries may be directed to Frank Morgan, Vice President of Investor Relations, at 615-344-2688 or frank.morgan@hcahealthcare.com, while media inquiries may be directed to Harlow Sumerford at 615-344-1851.
HCA Healthcare (NYSE:HCA) released preliminary results for the second quarter ended June 30, 2026 and revised its full‑year 2026 guidance. Q2 2026 revenues are expected to be about $20.230 billion versus $18.605 billion a year earlier. Net income attributable to HCA is forecast at approximately $1.699 billion, or $7.62 per diluted share, up from $1.653 billion, or $6.83 per share, in Q2 2025. Adjusted EBITDA is anticipated to be about $4.027 billion versus $3.849 billion.
Same facility admissions rose 2.5%, equivalent admissions 2.7% and ER visits 3.6%, while inpatient and outpatient surgeries declined 2.3% and 3.4%, respectively. HCA estimates a payer mix shift from increased uninsured volume reduced Q2 income before taxes by about $400 million. The company recognized roughly $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, mainly in Florida.
For 2026, HCA now guides revenues to $77.0–$79.5 billion, net income to $6.3–$6.7 billion, Adjusted EBITDA to $15.4–$16.1 billion, and diluted EPS to $28.70–$30.50, all lower than prior ranges. Estimated 2026 income impact from health insurance exchanges is revised to a negative $1.0–$1.2 billion, while expected benefit from Medicaid Supplemental Payment Programs increases to $300–$500 million. Capital expenditure guidance of $5.0–$5.5 billion excluding acquisitions is unchanged.
HCA Healthcare (NYSE:HCA) reported New England Journal of Medicine phase 3 data on exagamglogene autotemcel (exa-cel), a CRISPR-based cell therapy, in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia.
Among 26 enrolled children, all eight beta thalassemia patients followed long enough achieved ≥12 months transfusion independence, and all eight sickle cell patients remained free from severe vaso-occlusive crises for ≥12 months. HCA highlights its Sarah Cannon Transplant and Cellular Therapy Network, performing 1,600+ blood and marrow transplants and cellular therapies annually and expanding access to FDA-approved gene-editing treatments at multiple children's hospitals.
HCA Healthcare (NYSE:HCA) agreed to acquire The College of Health Care Professions (CHCP), a Texas-based allied healthcare educator serving over 8,000 students annually across 10 campuses and online. CHCP will retain its leadership under Chancellor and CEO Eric Bing. The deal awaits regulatory approval; terms were not disclosed.
HCA Healthcare (NYSE:HCA) reported outcomes from its seventh annual We Show Up for Our Communities days of service initiative. Colleagues supported 1,866 nonprofits, with 9,790 volunteers contributing more than 41,800 hours. In 2025, staff volunteered over 350,000 hours and the HCA Healthcare Foundation’s Middle Tennessee Fund awarded $8.3 million in grants to 227 nonprofits.
HCA Healthcare (NYSE: HCA) will present at the RBC Global Healthcare Conference on May 20, 2026 at 11:30am ET. A live audio webcast link and presentation materials will be posted in the Investor Relations section at www.hcahealthcare.com. Dates and times may change; check the IR site for updates.
HCA (NYSE: HCA) named Cynthia Cifuentes-Finkel senior vice president of marketing and corporate affairs, effective June 8, 2026. She will report to Mike McAlevey and lead enterprise marketing, corporate communications, and stakeholder engagement to support HCA’s growth priorities.
Cifuentes-Finkel brings 25+ years of leadership, including 15 years at Kaiser Permanente and experience overseeing a division serving nearly 5 million patients. She succeeds Deb Reiner, who retired after over 25 years of service.